Equities

Appili Therapeutics Inc

APLI:TOR

Appili Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.025
  • Today's Change-0.005 / -16.67%
  • Shares traded31.98k
  • 1 Year change-54.55%
  • Beta0.9744
Data delayed at least 15 minutes, as of Sep 20 2024 19:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Appili Therapeutics Inc share price to rise to 0.150 in the next year from the last price of 0.03.
High500.0%0.150
Med500.0%0.150
Low500.0%0.150

Earnings history & estimates in CAD

Earnings forecasts are not available for Appili Therapeutics Inc. On Aug 13, 2024, Appili Therapeutics Inc reported 1st quarter 2025 losses of -- per share.
Average growth rate0.00%
Annual earnings information is not available for Appili Therapeutics Inc.
Average growth rate-9.80%
More ▼

Revenue history & estimates in CAD

Revenue forecasts are not available for Appili Therapeutics Inc..
Average growth rate+2,096.18%
Annual revenue information is not available for Appili Therapeutics Inc..
Average growth rate-87.22%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.